Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Hawaii Health Digest.
Press releases published on September 4, 2025
ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
GlobeNewswire
·
September 4, 2025
Garching / Munich, Germany, September 4, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit …
Rakovina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
September 4, 2025
VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, today announced …
Lygos Clinic Launches VIP All-Inclusive Dental Tourism Packages for International Patients
GlobeNewswire
·
September 4, 2025
ISTANBUL, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Lygos Clinic, a leading dental center in Istanbul, has officially launched its new VIP all-inclusive dental tourism packages, designed to meet the rising global demand for premium, affordable cosmetic dentistry. …
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway
GlobeNewswire
·
September 4, 2025
AC Immune Sharpens Pipeline Focus with Operational Efficiencies Extending Cash Runway Strategic review by executive management yields increased pipeline focus and operational efficiencies with a workforce reduction of around 30% Increased emphasis on late- …
Onco3R Therapeutics Announces Approval of First Clinical Trial Application for Novel SIK3 inhibitor O3R-5671 in Autoimmune Diseases
GlobeNewswire
·
September 4, 2025
O3R-5671 is designed to overcome the limitations of first-generation SIK inhibitors, providing a potential new oral treatment option for multiple autoimmune diseases Clinical Trial Application approval marks Onco3R’s transition into a clinical-stage …
PulseSight Therapeutics Provides New Insights into the Role of Iron and Transferrin in AMD, Supporting its PST-611 Vectorized Therapy for Dry AMD/Geographic Atrophy at EURETINA 2025
GlobeNewswire
·
September 4, 2025
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- PulseSight Therapeutics, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology announces that its CSO, Thierry Bordet Ph.D., will present …
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
GlobeNewswire
·
September 4, 2025
MINNEAPOLIS and BRISBANE, Australia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR), a global structural heart company committed to designing, developing, and commercializing cutting- …
Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally Licensed
GlobeNewswire
·
September 4, 2025
Company expects to fully repay existing financial debts in 2026 NCX 470 NDA submissions in U.S. (H1 2026) and subsequently in China Milestones payable on U.S. NDA submission and on approval Glaukos extends NCX 1728 research agreement Future strategic …
Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entier
GlobeNewswire
·
September 4, 2025
4 septembre 2025 – publication à 7H30 Sophia Antipolis, France Nicox SA (Euronext Growth Paris : FR0013018124, ALCOX, éligible PEA-PME), une société internationale spécialisée en ophtalmologie, annonce aujourd’hui qu’elle prévoit de rembourser l’ …
Press Release: Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis
GlobeNewswire
·
September 4, 2025
Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, demonstrated statistically significant and clinically …
Communiqué de presse : L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique
GlobeNewswire
·
September 4, 2025
L’amlitelimab de Sanofi a atteint tous les critères d’évaluation principaux et secondaires clés dans l’étude de phase 3 COAST 1 menée chez des adultes et des adolescents atteints de dermatite atopique L’amlitelimab, administré toutes les quatre semaines ou …
Kuros Biosciences announces changes in the Board of Directors
GlobeNewswire
·
September 4, 2025
Ad-hoc announcement pursuant to Article 53 of the SIX listing rules Kuros Biosciences announces changes in the Board of Directors Schlieren (Zurich), Switzerland, September 4, 2025 – Kuros Biosciences (“Kuros” or the “Company”) a leader in next generation …
JUST ON SLEEP Officially Launches on Shopee Singapore, Redefining Sleep Safety and Wellness
GlobeNewswire
·
September 4, 2025
SINGAPORE, Sept. 03, 2025 (GLOBE NEWSWIRE) -- JUST ON SLEEP, a smart contactless sleep monitoring device developed by Sewon Intelligence, has recently launched in Singapore via Shopee, making advanced sleep wellness and safety solutions more accessible to …
ProductLife Group Expands to Deliver Localized Expertise & Enhanced Client Support in Japan
GlobeNewswire
·
September 4, 2025
PARIS, Sept. 04, 2025 (GLOBE NEWSWIRE) -- ProductLife Group (PLG) is proud to announce the opening of its newest office in Japan, reinforcing its commitment to meeting evolving client needs and market demands. This expansion enhances capacity, strengthens …
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes
GlobeNewswire
·
September 4, 2025
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter …